Roshanravan Neda, Ghaffari Samad, Hedayati Mehdi
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Diabetes Metab Syndr. 2020 Jul-Aug;14(4):637-639. doi: 10.1016/j.dsx.2020.05.022. Epub 2020 May 12.
The pandemic of coronavirus disease 2019 (COVID-19) is a global health emergency that poses a significant threat to world people's health. This outbreak causes major challenges to healthcare systems. Given the lack of effective treatments or vaccine for it, the identification of novel and safe drugs against COVID-19 infection is an urgent need. Angiotensin-converting enzyme 2 (ACE2) is not only an entry receptor of the SARS-CoV-2 virus, the virus that causes COVID-19, but also can protect from lung injury. In this view, we highlighted potential approaches to address ACE2-mediated SARS-CoV-2 virus, including 1) delivering an excessive soluble form of ACE2 (recombinant human ACE2: rhACE2) and 2) inhibition of the interaction between SARS-CoV-2 virus and ACE2 by some compounds with competitive effects (morphine and codeine). Further clinical trials in this regard can reveal a more definite conclusion against the COVID-19 disaster.
2019年冠状病毒病（COVID-19）大流行是一场全球卫生突发事件，对世界人民的健康构成重大威胁。此次疫情给医疗系统带来了巨大挑战。鉴于缺乏针对该疾病的有效治疗方法或疫苗，鉴定出新型且安全的抗COVID-19感染药物迫在眉睫。血管紧张素转换酶2（ACE2）不仅是导致COVID-19的SARS-CoV-2病毒的进入受体，还能保护免受肺损伤。基于此观点，我们重点介绍了应对ACE2介导的SARS-CoV-2病毒的潜在方法，包括1）递送过量的可溶性ACE2形式（重组人ACE2：rhACE2）以及2）通过一些具有竞争作用的化合物（吗啡和可待因）抑制SARS-CoV-2病毒与ACE2之间的相互作用。在这方面的进一步临床试验可以针对COVID-19灾难揭示更明确的结论。
